Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients.

Saved in:
Bibliographic Details
Title: Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients.
Authors: Vincenzi, B.1, Galluzzo, S.1, Santini, D.1, Rocci, L.1, Loupakis, F.2, Correale, P.3, Addeo, R.4, Zoccoli, A.1, Napolitano, A.1, Graziano, F.5, Ruzzo, A.6, Falcone, A.3, Francini, G.4, Dicuonzo, G.7, Tonini, G.1
Source: Annals of Oncology. May2011, Vol. 22 Issue 5, p1141-1146. 6p. 4 Charts, 2 Graphs.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdq550